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ABSTRACT
Importance: Spitzoid lesions are a group of melanocytic tumors characterized by 
spindle-like or epithelioid cells with variable malignant potential. While some spitzoid 
lesions are classified as evidently benign or malignant by clinic and histology, others 
present with unclear clinical and histological characteristics and are categorized as 
lesions of intermediate biologic potential. These lesions represent a challenge for 
pathologists and clinicians alike. No consensus on ancillary diagnostics and clinical 
management exists. Prediction of their clinical course is difficult. The implementation 
of ancillary diagnostics is currently subject of extensive discussions.
Observations: We report three cases of spitzoid lesions in three young female 
patients (3-, 15- and 17 years old) from a single reference center with different 
clinical and histological manifestations. In each case, uncertain clinical and 
histological presentation led to the stepwise application of additional diagnostics using 
immunohistochemistry and a custom next generation sequencing panel optimized for 
melanocytic lesions (MelArray). Combining ancillary diagnostics helped determine 
clinical management in all cases by characterizing the biology of these lesions.
Conclusions and Relevance: We illustrate how clinical, histological and molecular 
features contribute to an optimized management plan in these critical situations and 
present a possible algorithm for the assessment of spitzoid neoplasms.
INTRODUCTION
Spitzoid lesions are a diverse group of rapid-
growing melanocytic tumors characterized by spindle-
like or epithelioid cells. Certain spitzoid lesions show 
evidently benign or malignant clinic and histology, 
while others present with unclear characteristics and 
are therefore categorized as lesions of intermediate 
biologic potential [1]. These lesions are a challenge for 
pathologists and clinicians, as there is no consensus on 
ancillary diagnostics or clinical management [2]. As 
patients are typically young [2, 3], prediction of the 
clinical outcome is essential to determine if adjuvant 
treatment is necessary.
The implementation of ancillary diagnostics such 
as immunohistochemistry (IHC), comparative genomic 
hybridization (CGH) and next generation sequencing 
(NGS) is currently subject of extensive discussions.
The usefulness of IHC in these cases is widely 
accepted, although there is no consensus on which markers 
to apply [1, 2, 4]. Garola et al. suggest the use of a panel 
combining p16, HMB45 and Ki67 stainings [5]. Current 
research further suggests a stepwise implementation of 
additional diagnostics including CGH or NGS. However, 
for all diagnostics, no cut-offs or standardized panel 
recommendations exist [2]. 
MelArray is a customized NGS panel optimized for 
melanocytic lesions that focuses on 190 genes previously 
reported in melanoma [6].
 Case Report
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We use three cases to present the interplay between 
clinical presentation, pathology and molecular biology 




A 3-year-old female presented with a quickly 
developing lesion on the right calf. The parents had first 
noticed a flat, reddish macula at 29 months of age. Within 
4 months, it had grown in size and elevation and developed 
a verrucous aspect. Due to unclear clinical features, the 
lesion was totally excised in April 2019. Histology, IHC 
and MelArray were performed (see Figure 1). 
Considering atypical clinical presentation and 
histology with inconspicuous molecular characteristics, 
clinical follow-ups were recommended after total excision. 
The patient has been followed up for 9 months without 
relapse. 
Patient 2
A 15-year-old female presented with a 13 × 18 mm 
dome-shaped, pinkish papule on the lower right back. Right 
inguinal lymphadenopathy was detected concomitantly. 
The patient reported to have first noticed the skin lesion in 
October 2017 and an inguinal swelling in February 2019. A 
biopsy of the skin was taken in March 2019. Histology, IHC 
and MelArray were performed (see Figure 2).
Based on this diagnostic constellation, a re-excision 
with 1 cm safety margin was carried out shortly after. 
Fine needle aspiration of the enlarged right inguinal 
lymph node with a diameter of 1 cm and thereafter a 
modified lymphadenectomy was performed in April 2019.
Histology and IHC of the lymphadenectomy sample 
showed locoregional spreading.
A PET/CT performed before the operation showed 
no further manifestations of disease.
The family was informed about the uncertain 
prognostic outcome. We recommended a close follow-
up regimen with clinical assessments every 6 weeks and 
imaging every 3 months, alternating ultrasound and PET/
CT scans and no adjuvant therapy. After 9 months, no 
relapses have occurred.
Patient 3
A female was referred to our clinic in April 2017 at 
the age of 14. The girl initially presented with a 15 mm, 
asymmetrically pigmented lesion on her back. The lesion 
Figure 1: Diagnostics in benign spitzoid lesion. Clinical manifestation of lesion in January 2019 (A) and April 2019 (B) showing 
progression from small erythematous macula to verrucous papule. Histologically, the lesion showed pronounced verrucous hyperplasia 
of the epidermis. In the dermis there is a well demarcated dense infiltration of epitheloid cells with extensive cytoplasm presenting mild 
mitotic activity (H&E, original magnification 100×) (C) and (H&E, original magnification 40×) (D). p16 was homogenously positive in 
melanocytic cells (P16 staining, original magnification 40×) (E) and HMB45 was negative in the dermal compartment (H&E, original 
magnification 40×) (F). Ki67 was widely expressed in the dermal-epidermal junction in keratinocytes and some melanocytic cells (Ki67 
staining, original magnification 40×) (G). Denoised copy ratio depicts the ratio of copy numbers of the tissue analyzed compared to normal 
tissue gained from the same FFPE block. In this case, no CNVs were seen (H). No non-synonymous mutations were detected in the genes 
included in the MelArray panel.
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had been present for years but had increased in size and 
thickness. Upon biopsy, a distinctly malignant histology 
and IHC features were seen; MelArray was performed 
to assess mutational status (see Figure 3, Supplementary 
Figures 1 and 2).
The clinical management followed current melanoma 
guidelines: a re-excision with 2 cm safety margin and 
sentinel lymph node biopsy (SLNB) were performed. 
The SLNB showed a 2.5 mm metastasis.  Adjusted 
lymphadenectomy was carried out in a peripheral center 
and was tumor-free. The patient was treated with adjuvant 
Ipilimumab without complications from August to 
November 2017. Follow-ups took place every 3 months 
and showed no recurrence until February 2019, when 
multiple lymph node, lung and brain metastases were 
detected during routine diagnostics. The biggest brain 
metastasis was excised and irradiated stereotactically. 
Systemic immunotherapy with Ipilimumab and Nivolumab 
was initiated in March 2019. The patient had to discontinue 
immunotherapy due to progressive disease and myositis of 
the ocular muscles after her second and third infusions.
The patient is now undergoing targeted therapy 
with Dabrafenib and Trametinib since May 2019. She is 
followed up clinically every month, with imaging every 
3 months.
The last PET/CT performed in December 2019 
showed complete response of all extracranial lesions and 
cMRI showed stable disease.
DISCUSSION AND CONCLUSIONS
Variability of histologic classification [3, 7, 8] 
and the absence of standardized ancillary diagnostic or 
therapeutic algorithms [2] create insecurity concerning 
clinical management and prognosis of patients with 
spitzoid lesions [1, 9].
In our first patient, unremarkable IHC and molecular 
patterns lead us to believe that the biology of the lesion 
was most likely benign and a loose regimen with regular 
clinical follow-ups was chosen.
The lesion in our second patient showed regular nevus 
architecture with large cells in conventional histology. Focal 
Ki-67 activity raised concern. Additionally, NGS showed a 
variant in the RASA2 gene, a tumor-suppressor for which 
inactivating mutations are described in 5% of melanomas [10]. 
To our best knowledge, there are no published reports showing 
RASA2 alterations in spitzoid lesions, hence the significance 
of the variant documented in this lesion is unknown.
The frequency of non-synonymous coding 
mutations suggested an intermediate genetic instability. 
The constellation of clinical presentation of primary 
lesion, histology, IHC and NGS, lead us to postulate an 
intermediate biologic instability of the lesion. Although 
the tumor had already developed lymph node spreading, 
we expect a low risk of developing further metastases. 
In cases like hers, where prognosis is unpredictable, 
counseling of patients is crucial. A close follow-up 
Figure 2: Diagnostics in intermediate spitzoid lesion. Clinical presentation of the lesion in March 2019 (A). Conventional histology 
showed a lesion with nevoid architecture with an acanthotic epithelial reaction pattern. In the dermis there are abundant preferentially 
spindle cell shaped melanocytic cells presenting disconcerting deep infiltration as well as pleomorphic nuclei and mitotic activity. (H&E, 
original magnification 40×) (B) (H&E, original magnification 100×) (C). p16 immunoreactivity was seen as far as the deep dermis (P16 
staining, original magnification 40×) (D). Ki67 staining confirmed an increased fraction of cells undergoing mitotic proliferation. (Ki67 
staining, original magnification 100×) (E). HMB45 staining was negative in tumor cells (HMB45 staining, original magnification 40×) (F). 
CNV analysis showed no alterations in MelArray genes (G). 7 non-synonymous mutations (11 mut/Mb) were detected in MelArray genes. 
MelArray also showed a variant in the RASA2 gene (c876_877delinsTT) (H).
Oncotarget128www.oncotarget.com
Figure 3: Diagnostics in malignant spitzoid lesion. Clinical presentation of primary not available. Conventional histology showed 
a polypoid, asymmetrical lesion with irregular shouldering (H&E, original original magnification 40×). (A) Melanocytic nests and mutiple 
single cells, focally lining up in the junction zone  present in the atrophic epidermis with slight hyperkeratosis, spindle-like cells with 
polymorphic nuclei and pagetoid epidermal spread and lack of maturation in the dermis lead to the diagnosis of melanoma with a Breslow 
depth of 1.9 mm (H&E, original magnification 100×). (B) Denoised copy ratio and CNV analysis showed a high number of CNVs (1938 
CNVs). (C) 11 non-synonymous mutations (17.5 mut/Mb) were seen. A BRAF p.V600E (D) mutation as well as alterations in several other 
melanoma-relevant genes were detected. These included amplifications (such as CCND1 (chromosome 11)) and heterozygous losses (such 
as loss of CDKN2A (chromosome 9)) (see Supplementary Materials).
Figure 4: Proposed diagnostic and therapeutic algorithm [2]. IHC combining proliferative and melanocytic markers (for example 
Ki67, p16, HMB45). If lesion seems benign in histology and IHC, then further analysis might not be needed. If lesion shows unclear or 
malignant characteristics, MelArray should be performed. Management: probably benign lesions should be totally excised and followed up 
clinically, intermediate lesions should be excised with a safety margin and potentially receive SLNB, although this is still subject of fierce 
debate. Malignant lesions should be managed according to melanoma guidelines. 
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regimen was chosen in agreement with the family, with 
close clinical follow-ups and frequent imaging. Adjuvant 
immunotherapy was not recommended.
In our third patient, IHC corroborated with histology, 
showing distinct signs of malignancy. NGS showed 
BRAF (p.V600E) mutation as well as a variety of other 
mutations (see Supplementary Materials) and a high 
amount of copy number variants (CNVs) in the genes 
analyzed by MelArray. All technologies pointed towards 
high potential for malignant course of disease, supporting 
the clinicians’ decision to proceed according to melanoma 
guidelines including adjuvant immunotherapy. Our primary 
goal was to define the dignity of these lesions and find a 
suitable therapeutic strategy, rather than classify them by 
nomenclature. Nevertheless, we would like to note that, since 
Spitz nevi only rarely present BRAF (p.V600E) mutations 
[2, 11], whereas common melanocytic nevi often do [12], we 
decided to classify this lesion as spitzoid melanoma rather 
than Spitz melanoma. Hence, we would like to underline 
that, by using NGS as a part of a standardized diagnostic 
algorithm, we were able to differentiate between a lesion 
with traits typical for Spitz tumors versus other types of 
melanoma by analyzing it’s genetic hallmarks in a clinically 
and histologically malignant lesion with spitzoid traits.
The combination of specific IHC-staining and NGS 
gave valuable insight on lesion biology in all cases. As 
NGS accessibility increases, it is conceivable that it will 
play a role in routine assessment of biologic potential of 
spitzoid lesions in the near future. Although the mutational 
landscape of Spitz tumors differs from cutaneous 
melanoma [2, 4, 12], many of previously mentioned genetic 
alterations found in Spitz tumors [2, 11, 13] are mutations, 
amplifications and losses that are detectable by MelArray 
(as HRAS mutations, BAP1 mutations, TERTp mutations. 
see Supplementary Materials). A weakness of the use of 
this customized NGS panel for characterization of Spitz 
tumors is the lack of detectability of fusions, which make 
up a significant part of their genetic landscape [2, 11, 13].
However, information on mutational burden and 
CNV analysis allows us to estimate the genomic alteration 
burden that might reflect malignant potential, as multiple 
mutations and CNVs tend to be more common in lesions 
with higher malignancy [4, 14, 15].
We are confident that a standardized classification 
system, which routinely includes IHC and NGS, will give 
more clarity on spitzoid lesions in the near future [2, 16]. 
For centers rarely confronted with spitzoid lesions 
and technologies such as NGS are not readily available, 
we suggest cases be referred to reference centers for 
further assessment [2].
With these cases we portray three different clinical, 
histological and molecular manifestations of spitzoid 
lesions. All the information gained impacted the clinical 
management plan. Here we present a possible algorithm 
for the classification of biologic potential of spitzoid 
lesions (Figure 4).
Larger, multi-center validation studies and registries 
with long-term follow-up are needed to evaluate feasibility 
and clinical relevance of routine implementation.
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